Retrospective Clinical Evaluation of Platelet-Rich Plasma Application in Oral Surgery in Adults

Background: The primary objectives of platelet-rich plasma (PRP) therapy are to enhance the wound-healing process, reduce pain, and minimize the loss of productivity due to recovery time. Localized application of PRP, which is enriched with growth factors such as PDGF, TGF-β1, IGF-1, VEGF, and FGF-2, as well as interleukins (IL-1, IL-4, IL-6, IL-10, and IL-13), has been documented to accelerate the healing process by approximately 30–40%. This study aimed to assess the safety and efficacy of platelet-rich plasma (PRP) in enhancing outcomes following circumcision in male children. Methods: The patients were divided into two groups: one undergoing standard circumcision and the other receiving PRP application during circumcision. Pain scores, edema level, bleeding, local infection, and safety of PRP were evaluated. Results: This study evaluated 80 male children undergoing circumcision, divided into two groups: Group CS (n = 44) underwent classical circumcision, and Group PRP (n = 36) received PRP application. Median ages were comparable (p = 0.101). Penile edema occurred less frequently in the PRP group (5.6%) compared to the CS group (18.2%) (p = 0.089), with no severe edema observed in the PRP group. Postoperative bleeding was present in 6.8% of the CS group but absent in the PRP group (p = 0.110). Other complications, such as nausea (CS: 6.8%, PRP: 5.6%, p = 0.816), vomiting (CS: 4.5%, PRP: 2.8%, p = 0.679), local infection (CS: 2.3%, PRP: 0%, p = 0.363), wound dehiscence (CS: 2.3%, PRP: 0%, p = 0.363), and skin tunnel formation (CS: 6.8%, PRP: 2.8%, p = 0.409), showed no significant differences. No cases of necrosis, chordee, rotational anomaly, or secondary phimosis were observed. Safety analysis of PRP revealed minor complications during blood draw: hypotension in one patient (2.8%) and local ecchymosis in two patients (5.6%), resolving without intervention. During PRP application, one allergic reaction (2.8%) occurred, presenting as a transient rash that resolved spontaneously. Group PRP consistently reported lower pain scores than Group CS at all time points. Conclusions: PRP application during circumcision is safe. The findings provide preliminary but important evidence regarding the potential benefits of PRP in pediatric circumcision.

ObjectiveThe purpose of this meta-analysis is to evaluate the effect of the application of platelet-rich plasma (PRP) in spinal fusion surgery on the fusion rate of the spine.MethodsA comprehensive search of the PubMed, Embase, Cochrane Library, and Science Direct databases was conducted to identify randomized control trials (RCTs) or observational cohort studies that evaluated the efficacy and safety of PRP in spinal fusion. Data on final fusion rate, changes in the visual analog scale (VAS), estimated blood loss (EBL), and operative time was collected from the eligible studies for meta-analysis. Patients were divided into PRP and non-PRP groups according to whether PRP was used during the spinal fusion procedure.ResultsAccording to the selection criteria, 4 randomized controlled trials and 8 cohort studies with 833 patients and 918 levels were included. The outcomes indicated that PRP application is associated with a lower fusion rat (OR = 0.62, 95% CI: (0.43, 0.89), P = 0.009) at final follow-up (>24 months). Subgroup analysis showed a lower rate of spinal fusion in the PRP group compared to the non-PRP group (OR = 0.35, 95% CI: (0.21, 0.58), P < 0.001) when spinal fusion was assessed using only anterior-posterior radiographs. When the bone graft material was a combination of autologous bone + artificial bone, the spinal fusion rate was lower in the PRP group than in the non-PRP group (OR = 0.34, 95% CI: (0.16, 0.71), P = 0.004). The PRP and non-PRP groups showed no significant differences in VAS changes at the 24th postoperative month (WMD = 0.36, 95% CI: (−0.37, 1.09), P = 0.33); Application of PRP does not reduce the estimated blood loss (WMD = −86.03, 95% CI: (−188.23, 16.17), P = 0.10). In terms of operation time, using PRP does not prolong operation time (WMD = −3.74, 95% CI: (−20.53, 13.04), P = 0.66).ConclusionCompared with bone graft fusion alone, PRP cannot increase the rate of spinal fusion. Inappropriate methods of spinal fusion assessment or mixing PRP with artificial/allograft bone may have been responsible for the lower rate of spinal fusion in the PRP group.Systematic Review Registrationdoi: 10.37766/inplasy2022.5.0055

Objective To observe the short-term efficacy of intra-articular injection of platelet-rich plasma(PRP) and umbilical cord mesenchymal stem cells(MSCs) in the treatment of mild to moderate knee osteoarthritis. Methods A total of 200 cases of osteoarthritis of knee joint in Liaocheng People′s Hospital were collected. Inclusion creteria: Kellgren- Lawrence grade Ⅰ to Ⅲ patients with osteoarthritis of knee joint. Exclusion criteria: Kelgren-Lawrence grade Ⅳ osteoarthritis patients and inflammatory arthritis patients. According to the pseudo-random numbers generated by the computer, the patients with knee osteoarthritis were randomly divided into PRP+ MSC group, PRP group, MSC group and sodium hyaluronate (SH) group, 50 cases in each group. In PRP+ MSC group, 5 ml PRP and umbilical cord MSCs mixture were injected into articular cavity; in PRP group, 5 ml PRP was injected into articular cavity; in MSC group, 5 ml umbilical cord MSCs were injected into articular cavity; in SH group, 2.5 ml SH and triamcinolone acetonide injection were injected into articular cavity. After one, three, six and 12 months of treatment, the improvement of knee joint function was evaluated by visual analogue scale (VAS) and American Knee Association score (AKS); the changes of cytokines in joint fluid were detected by enzyme-linked immunosorbent assay (ELISA), and the Changes in articular cartilage before and after were evaluated by T2 Map sequence of MRI. Measurement data such as age, course, VAS score, AKS score, and cytokine content were analyzed by one-way ANOVA. Enumeration data such as sex ratio and disease degree of patients were analyzed by chi-square test. Results Among the 200 patients, 175 were followed up, 45 in PRP+ MSC group, 44 in PRP group, 43 in MSC group and 43 in SH group. There was no significant difference in the expression of cytokines in VAS, AKS and synovial fluid between the four groups before treatment (P >0.05). One month after treatment, the VAS scores of the four groups were lower than before, and the AKS scores were higher than before. There was significant difference between the groups (t=6.45, P 0.05). Three months later, VAS and AKS in SH group tended to be in the pre-treatment state, while no rebound was found in the other three groups. PRP+ MSC combined injection group was superior to PRP alone and MSC treatment groups. The difference between the four groups was statistically significant (F=7.84, 4.35; P <0.01). Three weeks after treatment, there was no significant change of cytokines in the joint fluid of SH group. The level of cytokines in the joint fluid of PRP+ MSC group was higher than that of PRP and MSC group (F=39.21, P <0.01). Six months after treatment, the average cartilage T2 values of PRP+ MSC group, PRP group, MSC group and SH group were (54.1±2.6)ms, (56.6±1.4)ms, (56.4±1.6)ms, (58.0±2.0)ms, respectively (F=30.63; P <0.05). Conclusion Intra-articular injection of platelet-rich plasma and umbilical cord mesenchymal stem cells can significantly improve the symptoms of patients with knee osteoarthritis and delay the progress of osteoarthritis. Key words: Osteoarthritis; Mesenchymal stromal cells; Platelet-rich plasma

The effectiveness of Platelet-Rich Plasma (PRP) in the treatment of patients with Achilles tendon rupture (ATR) and Achilles tendinopathy (AT) has been controversial. To assess PRP injections' effectiveness in treating ATR and AT. A comprehensive review of relevant literature was conducted utilizing multiple databases such as Cochrane Library, PubMed, Web of Science, Chinese Science and Technology Journal, EMBASE, and China Biomedical CD-ROM. The present investigation integrated randomized controlled trials that assessed the effectiveness of platelet-rich plasma injections in managing individuals with Achilles tendon rupture and tendinopathy. The eligibility criteria for the trials encompassed publications that were published within the timeframe of January 1, 1966 to December 2022. The statistical analysis was performed utilizing the Review Manager 5.4.1, the visual analogue scale (VAS), Victorian Institute Ankle Function Scale (VISA-A), and Achilles Tendon Thickness were used to assess outcomes. This meta-analysis included 13 randomized controlled trials, 8 of which were randomized controlled trials of PRP for AT and 5 of which were randomized controlled trials of PRP for ATR. PRP for AT at 6 wk [weighted mean difference (WMD) = 1.92, 95%CI: -0.54 to 4.38, I2 = 34%], at 3 mo [WMD = 0.20, 95%CI: -2.65 to 3.05, I2 = 60%], and 6 mo [WMD = 2.75, 95%CI: -2.76 to 8.26, I2 = 87%) after which there was no significant difference in VISA-A scores between the PRP and control groups. There was no significant difference in VAS scores between the PRP group and the control group after 6 wk [WMD = 6.75, 95%CI: -6.12 to 19.62, I2 = 69%] and 6 mo [WMD = 10.46, 95%CI: -2.44 to 23.37, I2 = 69%] of treatment, and at mid-treatment at 3 mo [WMD = 11.30, 95%CI: 7.33 to 15.27, I2 = 0%] after mid-treatment, the PRP group demonstrated better outcomes than the control group. Post-treatment patient satisfaction [WMD = 1.07, 95%CI: 0.84 to 1.35, I2 = 0%], Achilles tendon thickness [WMD = 0.34, 95%CI: -0.04 to 0.71, I2 = 61%] and return to sport [WMD = 1.11, 95%CI: 0.87 to 1.42, I2 = 0%] were not significantly different between the PRP and control groups. The study did not find any statistically significant distinction between the groups that received PRP treatment and those that did not, regarding the Victorian Institute of Sport Assessment - Achilles scores at 3 mo [WMD = -1.49, 95%CI: -5.24 to 2.25, I2 = 0%], 6 mo [WMD = -0.24, 95%CI: -3.80 to 3.32, I2 = 0%], and 12 mo [WMD = -2.02, 95%CI: -5.34 to 1.29, I2 = 87%] for ATR patients. Additionally, no significant difference was observed between the PRP and the control groups in improving Heel lift height respectively at 6 mo [WMD = -3.96, 95%CI: -8.61 to 0.69, I2 = 0%] and 12 mo [WMD = -1.66, 95%CI: -11.15 to 7.83, I2 = 0%] for ATR patients. There was no significant difference in calf circumference between the PRP group and the control group after 6 mo [WMD = 1.01, 95%CI: -0.78 to 2.80, I2 = 54%] and 12 mo [WMD = -0.55, 95%CI: -2.2 to 1.09, I2 = 0%] of treatment. There was no significant difference in ankle mobility between the PRP and control groups at 6 mo of treatment [WMD = -0.38, 95%CI: -2.34 to 1.58, I2 = 82%] and after 12 mo of treatment [WMD = -0.98, 95%CI: -1.41 to -0.56, I2 = 10%] there was a significant improvement in ankle mobility between the PRP and control groups. There was no significant difference in the rate of return to exercise after treatment [WMD = 1.20, 95%CI: 0.77 to 1.87, I2 = 0%] and the rate of adverse events [WMD = 0.85, 95%CI: 0.50 to 1.45, I2 = 0%] between the PRP group and the control group. The use of PRP for AT improved the patient's immediate VAS scores but not VISA-A scores, changes in Achilles tendon thickness, patient satisfaction, or return to sport. Treatment of ATR with PRP injections alone improved long-term ankle mobility but had no significant effect on VISA-A scores, single heel lift height, calf circumference or return to sport. Additional research employing more extensive sampling sizes, more strict experimental methods, and standard methodologies may be necessary to yield more dependable and precise findings.

Platelet-rich Plasma and Its Application in Clinical Trial

Hair loss profoundly affects women's physical appearance and psychological health. Platelet-rich plasma (PRP) therapy has gained attention as a potential treatment for female hair loss. This systematic review and meta-analysis aim to evaluate the efficacy and safety of PRP in treating different forms of female hair loss. A comprehensive search was conducted across PubMed, EMBASE, Scopus, Cochrane Library, Web of Science, and ClinicalTrials.gov from January 2000 to May 2024. The focus was on randomized controlled trials investigating PRP treatment for various types of hair loss in women. The research protocol is registered with International Prospective Register of Systematic Reviews (CRD42024556190). The quality of the studies was evaluated using the Cochrane risk of bias tool (RoB 2). A total of 21 studies comprising 628 participants were included in the analysis. PRP treatment was found to significantly enhance hair density and thickness. Additionally, there was a significant reduction in the number of hairs pulled in the PRP group. Adverse effects were generally mild and transient, with no notable difference in pain or discomfort between the PRP and control groups (risk ratio: 1.01; 95% CI: 0.87-1.18). PRP therapy effectively enhances hair density and thickness in women with hair loss, with a favorable safety profile. However, the effects of PRP on hair density and thickness vary with dosage, injection duration, and ethnicity, indicating the need for tailored treatment protocols.

CORR Synthesis: What Is the Role of Platelet-rich Plasma Injection in the Treatment of Tendon Disorders?

Healing of extraction sockets is a critical factor in oral and maxillofacial surgery, particularly when preserving alveolar bone and periodontal stability is essential. Platelet-rich plasma (PRP), an autologous concentrate of growth factors, has gained attention for its potential to enhance bone regeneration and soft-tissue healing. This study aimed to evaluate the clinical and radiographic outcomes of PRP application in extraction sockets after impacted mandibular third molar surgery. Forty patients who underwent impacted mandibular third molar extraction were divided into two groups according to clinical decision-making in conjunction with patient preference: the PRP group, in which PRP was applied in the extraction socket, and the non-PRP group, which received standard post-extraction care. Clinical parameters, including probing depth and wound closure, and radiographic assessments of alveolar bone level and bone density were recorded at baseline, one month, three months, and six months postoperatively. The application of PRP resulted in significant improvements in alveolar bone preservation and periodontal health, with a notable reduction in probing depth compared to the non-PRP group. Although PRP did not show a significant difference in bone density between the groups, a sustained increase over time suggested a positive effect on bone remodeling. PRP also accelerated wound healing, with initial dehiscence observed, but improved closure by day seven, indicating a biphasic influence on tissue repair. PRP demonstrated potential benefits in enhancing soft and hard tissue healing after mandibular third molar extraction. Its ability to promote periodontal stability and wound closure suggests its clinical utility for oral surgical procedures. However, larger randomized controlled trials with extended follow-up are needed to establish standardized protocols and confirm their long-term efficacy.

Background. The clinical evidence is conflicted on whether platelet‐rich plasma (PRP) therapies have a positive effect on tendon healing and improved functional outcomes. Purpose. To evaluate the potentials of intraoperative injection PRP on the speed and quality of healing in patients undergoing arthroscopic repair for small to medium rotator cuff tears. Methods. A total of 86 patients scheduled for arthroscopic single‐row repair of small to medium rotator cuff tears were assigned to undergo either PRP injection (PRP group) or conventional repair (control group). The PRP group (N = 43) consisted of patients who received an intraoperative injection of liquid PRP. The control group (N = 43) consisted of patients who did not receive that treatment. The visual analogue scale (VAS) for pain before treatment and at 1, 14 days, 3, 6, and 24 months after surgery were recorded. The clinical outcomes were assessed by the University of California, Los Angeles (UCLA) and Constant scores before treatment and at 3, 6, and 24 months after surgery and magnetic resonance imaging or ultrasound examination at 24 months. Patient satisfaction and retear rate were also assessed. Results. No statistical differences in baseline characteristics such as age, gender, dominant arm, and tear size were observed between the two groups (P &gt; 0.05). For the PRP group, the mean operation time was 40.22 minutes, and for the control group, the mean operation time was 36.3 minutes. There was a statistically significant difference (P = 0.036). After surgery, all VAS measurements significantly decreased over time until final follow‐up in both groups. No significant difference between the 2 groups was found for any VAS pain measurement at any time point except for the VAS at 1 day postoperatively, which was significantly lower in the PRP group (2.39 ± 1.03) than that in the control group (3.21 ± 1.85) (P = 0.014). Analysis of the PRP and control groups demonstrated a statistically significant improvement in UCLA and Constant scores from baseline to the 3‐, 6‐, and 24‐month follow‐up assessments (P &lt; 0.05). However, no significant intergroup differences were observed in the clinical scores between the three follow‐up time points (P &gt; 0.05). At the 24‐month follow‐up, patient satisfaction rates reached 95.65% and 93.48% for the PRP and control groups, respectively. The retear rate of the PRP group (2/43, 4.65%) was lower than that of the control group (6/43, 13.95%). Conclusions. Although the pain at 1 day after surgery and the retear rate in the PRP group were significantly lower than those in the control group, the liquid PRP injection did not promote better clinical outcomes at the 2‐year follow‐up.

Objective To investigate the effect of autologous platelet rich plasma (PRP) gel in arthroscopic rotator cuff repair. Methods All of 44 patients with rotator cuff tear undergent arthroscopic rotator cuff repair were randomly divided into two groups: PRP group (22 patients were received autologous PRP and hemocoagulase) and normal saline (NS) group (22 patients were received NS and hemocoagulase). All patients had the same accelerated rehabilitation protocol and were followed up in 1, 3, 12 months. Evaluation consisted of inflammatory reaction, wound healed, visual analogue scores (VAS), University of California at Angeles (UCLA) Shoulder Scores and American Shoulder and Elbow Surgeons (ASES) Scores. Results After operation, no inflammatory reaction was in 20 cases of PRP group and 19 cases of NS group, mid inflammatory reaction 1 case in PRP group and 2 cases in NS group, moderate inflammatory reaction 1 case in PRP group and 1 case in NS group. Wound healed by first intention in all of PRP group and 21 patients of NS group. In PRP group, the preoperative, 3 months and 12 months postoperative VAS were 6.6±2.0, 3.4±1.8, 1.8±1.3, UCLA were 15.2±2.9, 24.3±2.7, 32.4±2.1, ASES were 35.6±12.4, 63.4±10.4, 92.3±7.5. In NS group, the preoperative, 3 months and 12 months postoperative VAS were 6.7±1.9, 4.6±1.9, 2.0±1.2, UCLA were 14.8±3.0, 21.2±2.5, 31.7±2.3, ASES were 32.7±13.8, 55.8±11.8, 90.7±8.1. Three months postoperative VAS, UCLA, ASES were statistically significant differenece in PRP group and NS group. Twelve months postoperative VAS, UCLA, ASES were not statistically significant differenece in the two groups. Conclusion Using autologous PRP gel in arthroscopic rotator cuff repair can speed up the healing of operation incision with no adverse effect, reduce pain in the postoperation three months, accelerate the rotator cuff repair and recovery of the function of shoulder joint. It has good short-term clinical effect. Key words: Platelet rich plasma; Shoulder; Lacerations; Reconstructive surgical procedures

Background: Platelet-rich plasma (PRP) and hyaluronic acid (HA) are 2 nonoperative treatment options for knee osteoarthritis (OA) that are supposed to provide symptomatic relief and help delay surgical intervention. Purpose: To systematically review the literature to compare the efficacy and safety of PRP and HA injections for the treatment of knee OA. Study Design: Meta-analysis of level 1 studies. Methods: A systematic review was performed by searching PubMed, the Cochrane Library, and Embase to identify level 1 studies that compared the clinical efficacy of PRP and HA injections for knee OA. The search phrase used was platelet-rich plasma hyaluronic acid knee osteoarthritis randomized. Patients were assessed via the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), visual analog scale (VAS) for pain, and Subjective International Knee Documentation Committee (IKDC) scale. A subanalysis was also performed to isolate results from patients who received leukocyte-poor and leukocyte-rich PRP. Results: A total of 18 studies (all level 1) met inclusion criteria, including 811 patients undergoing intra-articular injection with PRP (mean age, 57.6 years) and 797 patients with HA (mean age, 59.3 years). The mean follow-up was 11.1 months for both groups. Mean improvement was significantly higher in the PRP group (44.7%) than the HA group (12.6%) for WOMAC total scores (P < .01). Of 11 studies based on the VAS, 6 reported PRP patients to have significantly less pain at latest follow-up when compared with HA patients (P < .05). Of 6 studies based on the Subjective IKDC outcome score, 3 reported PRP patients to have significantly better scores at latest follow-up when compared with HA patients (P < .05). Finally, leukocyte-poor PRP was associated with significantly better Subjective IKDC scores versus leukocyte-rich PRP (P < .05). Conclusion: Patients undergoing treatment for knee OA with PRP can be expected to experience improved clinical outcomes when compared with HA. Additionally, leukocyte-poor PRP may be a superior line of treatment for knee OA over leukocyte-rich PRP, although further studies are needed that directly compare leukocyte content in PRP injections for treatment of knee OA.

It was reported that platelet rich plasma can reduce the degeneration of articular cartilage. The purpose of this study was to investigate the effect of platelet rich plasma on Wnt/beta-catenin signal transduction in rabbit chondrocytes. Platelet rich plasma was prepared from the ear vein blood of 3-mo old New Zealand white rabbits. Chondrocytes were isolated from knee cartilage and cultured. The cell identification and the effect of platelet rich plasma on the viability of chondrocytes were measured by the C-terminal telopeptide II and proteoglycan staining. Chondrocytes were divided into 5 groups, control group, interleukin-1 beta group, platelet rich plasma (100 x dilutions) group, Dickkopf WNT signaling pathway inhibitor 1 (100 ng/mL) group and Dickkopf WNT signaling pathway inhibitor 1+platelet rich plasma group. After being treated with interleukin-1 beta (50 μL, 10 μg/mL) for 24 h, the morphology of chondrocytes was observed by an electron microscope. The levels of C-terminal telopeptide II and cartilage oligomeric matrix protein in the culture medium were determined by enzyme linked immunosorbent assay. The messenger RNA and protein expression levels of Wnt-1, beta-catenin and glycogen synthase kinase 3 beta were detected by Real-time polymerase chain reaction and Western blot respectively. Platelet rich plasma promotes the proliferation of chondrocytes. The chondrocytes in the interleukin-1 beta group showed an ultrastructural abnormality, which was not obvious in platelet rich plasma group, Dickkopf WNT signaling pathway inhibitor 1group, and Dickkopf WNT signaling pathway inhibitor 1+platelet rich plasma group. The concentrations of C-terminal telopeptide II and cartilage oligomeric matrix protein in the interleukin-1 beta group were higher than those in the control group, platelet rich plasma group, Dickkopf WNT signaling pathway inhibitor 1group and Dickkopf WNT signaling pathway inhibitor 1+platelet rich plasma group. Compared with the control group, platelet rich plasma group, Dickkopf WNT signaling pathway inhibitor 1group and Dickkopf WNT signaling pathway inhibitor 1+platelet rich plasma group, the expression of Wnt1 and beta-catenin was higher and the level of glycogen synthase kinase 3 beta was lower in the interleukin-1 beta group. Platelet rich plasma may protect interleukin-1 beta activated chondrocytes by inhibiting Wnt/beta-catenin signal.

The synergistic and protective effect of platelet-rich plasma (PRP) added to methlyprednisolone (MP) has been demonstrated via in-vitro studies. However, there is no report in the literature about this issue. The aim of this study was to evaluate clinical outcomes of intra-articular (IA) MP injection prior to PRP injection in comparison with single-dose MP and PRP injections alone in patients with knee osteoarthritis (OA). The treatment groups were "PRP group" (n= 37) who underwent single-dose IA PRP injection, "PRP + MP group" (n= 40) who underwent MP injection one week prior to single-dose PRP injection, and "MP group" (n= 38) who underwent single-dose MP injection. Visual Analog Scale (VAS) and The Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores were applied at first admission and at 1st, 3rd, 6th, and 12th month follow-ups. At the end of the 1st month, WOMAC score in PRP + MP group was significantly lower than PRP group. At the 3rd month, WOMAC score in PRP + MP group was significantly lower than PRP and MP groups. At the 6th month, VAS and WOMAC score in PRP + MP group was significantly lower than MP group. At the end of the 12th month, no significant difference was observed among three groups in VAS and WOMAC scores. According to our results, IA MP injection prior to PRP injection resulted in significantly better clinical outcomes compared to PRP and MP injections alone in patients who had mild to moderate knee OA.

Background:To evaluate the efficacy and safety of platelet-rich plasma (PRP) in the treatment of CTS by meta-analysis.Methods:Wanfang database, CNKI, VIP database, China Biological Literature Database, PubMed, Embase and Cochrane were searched for RCTS about PRP in the treatment of patients with CTS published up to October 2024. The PRP treatment group was treated with PRP on the basis of conventional treatment for CTS. The control group was treated with conventional conservative treatment of CTS. The main evaluation index of meta-analysis was BCTQ severity score. The secondary outcome measures were cross-sectional area of the median nerve, SNCV, DML, and VAS of pain.Results:A total of 7 studies involving 365 patients were included in this meta-analysis. There were 183 patients in PRP group and 182 patients in control group. The results of meta-analysis showed that compared with the conventional treatment group, the PRP group had significant reductions in the symptom severity scale at 1, 3, and 6 months and the functional status scale at 3 and 6 months (P < .05). Compared with the conventional treatment group, PRP group increased the cross-sectional area of median nerve at 1 month but decreased the cross-sectional area of median nerve at 3 and 6 months, and the differences were not statistically significant (P > .05). The Sensory nerve conduction velocity of PRP treatment group was lower than that of conventional control group at 1 (P < .0001), 3 (P = .35) and 6 (P = .69) months after treatment. Compared with the conventional treatment group, the PRP treatment group increased distal motor latency at 1, 3, and 6 months, but the difference was not statistically significant. Compared with the conventional control group, the PRP treatment group decreased the visual analogue scale of pain at 1 (P = .56) and 3 (P = .02) months. There were no serious adverse reactions after PRP treatment in the 4 studies which recorded adverse reactions.Conclusion:PRP is a safe and effective treatment for patients with CTS. PRP can improve the subjective efficacy of patients with CTS but has little effect on the cross-sectional area of median nerve, SNCV, and DML.

Introduction: This study aimed, effect of platelet-rich plasma (PRP) on soft tissue healing after mandibular third molar surgery. Materials &amp; Methods: In this semi-blinded clinical trial study,30 selected patients requiring surgical extraction of soft tissue impacted mandibular third molar participated from cases referred to the Department of Surgery, Faculty of Dentistry, Isfahan Azad University 2017.Patients divided into both test and control groups. PRP was placed in the extracted socket of the test group, whereas the control group had no PRP. Arzhangian standard kit utilized for preparation of PRP. The outcome variables in this study were pain, swelling, inter incisal mouth opening, wound dehiscence, dry socket, bleeding, and tissue color. The collected data analyzed using statistical tests followed independent T-test, Mann-Whitney, and fisher (p value &lt; 0.05). Results: The mean postoperative pain score (Visual Analog Scale) lowered for the test group after several wound dehiscence on the third and seventh days after surgery which was statistically significant (p value &lt; 0.001). Although the mean bleeding time on the third day after surgery decreased in the test group, this difference was not statistically significant (p value = 0.59). There were no statistically significant between both groups for The dry socket incidence on the seventh day and the mean of inter incisal mouth opening in the third and seventh days after surgery as well. Conclusion: The usage of topical PRP has beneficial advantages on soft tissue healing after mandibular third molar surgery. Unlike the control group, The PRP group provided reduced pain and better soft tissue healing.